Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease in high-risk type 2 diabetes​

Matthew A Cavender¹; Nikolaus Marx²; Sharon L Mulvagh³; John E Deanfield⁴; John B Buse¹; Silvio E Inzucchi⁵; Rodica Pop‑Busui⁶; Johannes FE Mann^7,8; Scott S Emerson⁹; Neil R Poulter¹⁰; Mads DM Engelmann¹¹; G Kees Hovingh¹¹; Alberto Lorenzatti¹²; Aytekin Oguz¹³; Jose F Kerr Saraiva¹⁴; Robinson Sanchez Garcia¹⁵; Søren Tetens Hoff¹¹; Derrick Musinga¹¹; Ecenur Guder Arslan¹¹; Darren K McGuire¹⁶; on behalf of the SOUL study group